Veracyte Inc
NASDAQ:VCYT
Intrinsic Value
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. [ Read More ]
The intrinsic value of one VCYT stock under the Base Case scenario is 15.08 USD. Compared to the current market price of 19.2 USD, Veracyte Inc is Overvalued by 21%.
Valuation Backtest
Veracyte Inc
Run backtest to discover the historical profit from buying and selling VCYT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Veracyte Inc
Current Assets | 285.6m |
Cash & Short-Term Investments | 216.5m |
Receivables | 40.4m |
Other Current Assets | 28.8m |
Non-Current Assets | 829.3m |
PP&E | 30.9m |
Intangibles | 791.6m |
Other Non-Current Assets | 6.8m |
Current Liabilities | 61.2m |
Accounts Payable | 12.9m |
Accrued Liabilities | 43.5m |
Other Current Liabilities | 4.8m |
Non-Current Liabilities | 9.6m |
Other Non-Current Liabilities | 9.6m |
Earnings Waterfall
Veracyte Inc
Revenue
|
361.1m
USD
|
Cost of Revenue
|
-112.9m
USD
|
Gross Profit
|
248.1m
USD
|
Operating Expenses
|
-265.6m
USD
|
Operating Income
|
-17.4m
USD
|
Other Expenses
|
-57m
USD
|
Net Income
|
-74.4m
USD
|
Free Cash Flow Analysis
Veracyte Inc
What is Free Cash Flow?
VCYT Profitability Score
Profitability Due Diligence
Veracyte Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
Veracyte Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
VCYT Solvency Score
Solvency Due Diligence
Veracyte Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Veracyte Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VCYT Price Targets Summary
Veracyte Inc
According to Wall Street analysts, the average 1-year price target for VCYT is 31.45 USD with a low forecast of 21.21 USD and a high forecast of 38.85 USD.
Ownership
VCYT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
VCYT Price
Veracyte Inc
Average Annual Return | 8.67% |
Standard Deviation of Annual Returns | 50.21% |
Max Drawdown | -81% |
Market Capitalization | 1.5B USD |
Shares Outstanding | 78 440 000 |
Percentage of Shares Shorted | 5.48% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 761 full-time employees. The company went IPO on 2013-10-30. The firm offers customized biomarker testing and analytical services. The company offers a complete range of in vitro diagnostic (IVD) and companion diagnostic development services to biopharmaceutical companies and diagnostic companies. The company offers tests across various diseases, which include Afirma Genomic Sequencing Classifier for thyroid cancer; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer; Prosigna Breast Cancer Assay for breast cancer; Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer; Envisia Genomic Classifier test for interstitial lung diseases; Decipher Bladder Genomic Classifier test for bladder cancer and Immunoscore Colon Cancer Test for colon cancer. The company also offers Immunogram, a spatial molecular analysis and bioinformatics tool that integrates genomic, transcriptomic and proteomic data to help researchers understand the intricacies of the tumor immune microenvironment.
Contact
IPO
Employees
Officers
The intrinsic value of one VCYT stock under the Base Case scenario is 15.08 USD.
Compared to the current market price of 19.2 USD, Veracyte Inc is Overvalued by 21%.